S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
S&P 500   4,701.21 (+0.31%)
DOW   35,754.75 (+0.10%)
QQQ   399.61 (+0.45%)
AAPL   175.08 (+2.28%)
MSFT   334.97 (+0.01%)
FB   330.56 (+2.40%)
GOOGL   2,963.73 (+0.62%)
AMZN   3,523.16 (+0.00%)
TSLA   1,068.96 (+1.64%)
NVDA   318.26 (-1.85%)
BABA   125.08 (-0.37%)
NIO   35.05 (+5.83%)
CGC   10.94 (+2.82%)
AMD   145.24 (+0.27%)
GE   98.28 (+0.75%)
MU   86.02 (+0.22%)
T   23.17 (+0.39%)
F   19.81 (-0.75%)
DIS   153.34 (+1.68%)
PFE   51.40 (-0.62%)
AMC   32.35 (+4.22%)
ACB   6.57 (+2.98%)
BA   211.03 (+1.05%)
NASDAQ:ARWR

Arrowhead Pharmaceuticals Stock Forecast, Price & News

$73.96
+2.29 (+3.20%)
(As of 12/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$71.05
$74.77
50-Day Range
$58.09
$82.51
52-Week Range
$57.92
$93.66
Volume
660,639 shs
Average Volume
739,831 shs
Market Capitalization
$7.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.29
30 days | 90 days | 365 days | Advanced Chart
Receive ARWR News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Arrowhead Pharmaceuticals logo

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
232
Year Founded
N/A

Sales & Book Value

Annual Sales
$138.29 million
Book Value
$3.92 per share

Profitability

Net Income
$-140.85 million
Net Margins
-101.85%
Pretax Margin
-101.85%

Debt

Price-To-Earnings

Miscellaneous

Free Float
100,610,000
Market Cap
$7.71 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/22/2021
Today
12/08/2021
Next Earnings (Estimated)
2/03/2022
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

1.88 out of 5 stars

Medical Sector

749th out of 1,394 stocks

Pharmaceutical Preparations Industry

357th out of 674 stocks

Analyst Opinion: 2.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions

Is Arrowhead Pharmaceuticals a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arrowhead Pharmaceuticals stock.
View analyst ratings for Arrowhead Pharmaceuticals
or view top-rated stocks.

How has Arrowhead Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARWR shares have increased by 159.0% and is now trading at $73.96.
View which stocks have been most impacted by COVID-19
.

When is Arrowhead Pharmaceuticals' next earnings date?

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Arrowhead Pharmaceuticals
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings data on Monday, November, 22nd. The biotechnology company reported ($0.61) EPS for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.65. Arrowhead Pharmaceuticals had a negative net margin of 101.85% and a negative trailing twelve-month return on equity of 32.27%. During the same quarter in the previous year, the company earned ($0.48) earnings per share.
View Arrowhead Pharmaceuticals' earnings history
.

What price target have analysts set for ARWR?

7 equities research analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' shares. Their forecasts range from $45.00 to $110.00. On average, they anticipate Arrowhead Pharmaceuticals' share price to reach $89.25 in the next year. This suggests a possible upside of 20.7% from the stock's current price.
View analysts' price targets for Arrowhead Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the following people:
  • Christopher Richard Anzalone, President, Chief Executive Officer & Director
  • Kenneth Allen Myszkowski, Chief Financial Officer
  • Javier San Martin, Chief Medical Officer
  • Jeff Ketelhut, Vice President-Information Technology & Systems
  • Patrick C. O'brien, Secretary & Chief Compliance Office

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), salesforce.com (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.45%), Johnson & Johnson (3.13%), Invesco Ltd. (2.22%), Geode Capital Management LLC (1.72%), Credit Suisse AG (1.39%) and First Manhattan Co. (1.08%). Company insiders that own Arrowhead Pharmaceuticals stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends for Arrowhead Pharmaceuticals
.

Which major investors are selling Arrowhead Pharmaceuticals stock?

ARWR stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Invesco Ltd., Janus Henderson Group PLC, Alliancebernstein L.P., Renaissance Technologies LLC, Principal Financial Group Inc., and Eagle Asset Management Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, and William D Waddill.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Arrowhead Pharmaceuticals stock?

ARWR stock was bought by a variety of institutional investors in the last quarter, including Johnson & Johnson, Farallon Capital Management LLC, Nordea Investment Management AB, Point72 Asset Management L.P., Morgan Stanley, CastleArk Alternatives LLC, Neuberger Berman Group LLC, and UBS Group AG.
View insider buying and selling activity for Arrowhead Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $73.96.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals has a market capitalization of $7.71 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140.85 million in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

Arrowhead Pharmaceuticals employs 232 workers across the globe.

What is Arrowhead Pharmaceuticals' official website?

The official website for Arrowhead Pharmaceuticals is www.arrowheadpharma.com.

Where are Arrowhead Pharmaceuticals' headquarters?

Arrowhead Pharmaceuticals is headquartered at 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at (626) 304-3400, via email at [email protected], or via fax at 626-304-3401.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.